Checked.be
Active
BE 0871.241.924Private limited company
DR RASOULI
Pastoor Van Neylenstraat 21 ·2440 Geel, Belgium· 21 yrs active
Sector: Specialist medical practice
(86220)
Conclusion
DR RASOULI has been active since 2005 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €2.07M and a net result of €371k. Equity is growing by ~9.4% per year across the filed fiscal years. Its solvency ranks better than 83% of 2244 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is < 0.1% (very low).
Based on the State Gazette, CBE and 5 annual accounts.
Key figures
| Equity | €2.07M |
| Net result | €371k |
| Staff (FTE) | 2.5 |
| Better than sector | 83% |
Financial profile
92
/ 100
Exceptional profile, strong across almost every axis.
All 5 axes are computed from data Checked has read.
Health
93
Profitability
89
Solvency
100
Growth
78
Stability
100
Bankruptcy probability (12 mo)
Risk Assessment
0 / 100
Low riskTrust signals
Long-established
Founded in 2005, 21 years in business.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Checked score
93
/ 100
Excellent
Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.
Indicative credit limit
€190k
estimate, not credit advice
Score history
93
2021
93
2022
100
2023
100
2024
93
2025
purely financial, excl. current insolvency signals
Score components
Liquidity
Current ratio 8.97 (≥ 1.5)
+10
Quick ratio
Quick ratio 8.97 (≥ 1.0)
+5
Leverage
Debt/equity 0.12 (< 1.0)
+10
Profitability
ROE 18% (≥ 10%)
+10
Interest coverage
Interest coverage 129.8× (≥ 3×)
+8
Profit trend
Net profit down YoY
-3
Equity growth
Equity growing YoY
+3
Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.
Financial overview
Annual accounts filed on 15-06-2026 with the NBB · fiscal year 2025 · abbreviated schema
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
growing
Equity: growth of ~9.4%/year over 5 fiscal years, indicative, assuming unchanged policy.
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
Sector comparison
Fiscal year 2025 · NACE 86, Human health activities · compared within the same schema type (abbreviated schema)
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 89.6% | 59.8% | |
| Net result | €371k | €121k | |
| Equity | €2.07M | €395k | |
| Gross operating margin | €707k | €301k | |
| Staff costs | €168k | €111k |
€535k
-2.6%
21-25
€371k
-5.6%
21-25
€394k
-4.3%
21-25
€2.32M
+7.2%
21-25
€2.07M
+7.0%
21-25
€1.92M
+8.5%
21-25
3
0.0%
21-25
€168k
+2.1%
21-25
€171k
-6.4%
21-25
€235k
+1.7%
21-25
€241k
+8.8%
21-25
€241k
+8.8%
21-25
8.97
-0.3%
21-25
8.97
-0.3%
21-25
89.6%
-0.2%
21-25
0.12
+1.7%
21-25
17.9%
-11.7%
21-25
16.0%
-11.9%
21-25
129.82
-21.4%
21-25
Figures by fiscal year and ratios
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Deposit | abbreviated schema | abbreviated schema | abbreviated schema | abbreviated schema | abbreviated schema |
| Revenue | - | - | - | - | - |
| EBITDA | €535k | €549k | €501k | €446k | €532k |
| Net profit | €371k | €393k | €342k | €296k | €332k |
| Cash flow | €394k | €411k | €372k | €340k | €379k |
| Staff costs | €168k | €165k | €155k | €158k | €129k |
| Income taxes | €171k | €183k | €152k | €130k | €159k |
| Dividends | €235k | €231k | €149k | €125k | €336k |
| Total assets | €2.32M | €2.16M | €1.88M | €1.76M | €1.56M |
| Equity | €2.07M | €1.94M | €1.78M | €1.59M | €1.41M |
| Debt | €241k | €221k | €104k | €171k | €148k |
| of which ≤ 1y | €241k | €221k | €104k | €171k | €148k |
| of which > 1y | - | - | - | - | - |
| Working capital | €1.92M | €1.77M | €1.60M | €1.40M | €1.19M |
| Employees (FTE) | 2.5 | 2.5 | 2.4 | 2.5 | 3.0 |
Ratios (computed)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Current ratio | 8.97 | 8.99 | 16.36 | 9.14 | 9.04 |
| Quick ratio | 8.97 | 8.99 | 16.36 | 9.14 | 9.04 |
| Working capital ratio | 82.8% | 81.9% | 85.1% | 79.4% | 76.0% |
| Solvency | 89.6% | 89.8% | 94.5% | 90.2% | 90.6% |
| Debt / equity | 0.12 | 0.11 | 0.06 | 0.11 | 0.10 |
| Long-term debt ratio | - | - | - | - | - |
| Interest coverage | 129.82 | 165.16 | 137.91 | 52300.10 | 2059.36 |
| Gross margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| ROA | 16.0% | 18.2% | 18.2% | 16.8% | 21.3% |
| ROE | 17.9% | 20.2% | 19.2% | 18.6% | 23.5% |
| EBITDA margin | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - |
| Days inventory (DSI) | - | - | - | - | - |
Balance-sheet composition 2025
Full annual accounts (23 line items)
Filed balance sheet and income statement, exactly as deposited with the NBB.
| Line item | Code | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Balance sheet, Assets | ||||||
| TOTAL ASSETS | 20/58 | €2.32M | €2.16M | €1.88M | €1.76M | €1.56M |
| Fixed assets | 21/28 | €156k | €170k | €176k | €191k | €228k |
| Tangible fixed assets | 22/27 | €156k | €170k | €176k | €191k | €228k |
| Current assets | 29/58 | €2.16M | €1.99M | €1.71M | €1.57M | €1.33M |
| Amounts receivable within one year | 40/41 | €439k | €418k | €393k | €373k | €346k |
| Investments | 50/53 | €1.06M | €950k | €900k | - | - |
| Cash & bank | 54/58 | €656k | €622k | €413k | €1.19M | €989k |
| Balance sheet, Equity & liabilities | ||||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €2.32M | €2.16M | €1.88M | €1.76M | €1.56M |
| Equity | 10/15 | €2.07M | €1.94M | €1.78M | €1.59M | €1.41M |
| Contributions / capital | 10/11 | €13k | €13k | €13k | €13k | €13k |
| Reserves | 13 | €2.06M | €1.93M | €1.77M | €1.57M | €1.40M |
| Accumulated profits (losses) | 14 | €0 | - | - | - | - |
| Amounts payable | 17/49 | €241k | €221k | €104k | €171k | €148k |
| Amounts payable within one year | 42/48 | €241k | €221k | €104k | €171k | €148k |
| Trade debts payable within one year | 44 | €16k | €10k | €11k | €4k | €13k |
| Income statement | ||||||
| Gross operating margin | 9900 | €707k | €717k | €659k | €606k | €663k |
| Operating result | 9901 | €512k | €530k | €470k | €402k | €485k |
| Financial income | 75 | €34k | €48k | €28k | €23k | €7k |
| Financial charges | 65 | €4k | €3k | €4k | €9 | €258 |
| Result before taxes | 9903 | €542k | €575k | €494k | €425k | €492k |
| Income taxes | 67/77 | €171k | €183k | €152k | €130k | €159k |
| Net result for the period | 9904 | €371k | €393k | €342k | €296k | €332k |
| Result to be appropriated | 9905 | €371k | €393k | €342k | €296k | €332k |
Legal Structure
| NACE primary | Specialist medical practice(86220) |
| Legal form | Private limited company(610) |
| Incorporation | 17-01-2005 |
| Status | Active |
| Postal code | 2440 |
Establishment units
Dr. Rasoui
since 20042.232.768.863
Real-estate footprint
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 13008H0366/00F002 | Flanders | 493 m² | 1 · 222 m² | 17.0 m · 4 fl. |
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Updates
Next filing, fiscal year 2026, expected by
2026
15-06
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
2025
31-12
Financial
Equity above €2MEq €2.07M ▲7%
5 profitable years in a row build equity to €2.07M.
30-06
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
31-12
Financial
Highest result since 2021net €393k ▲14.9%
Operating result €530k, net result €393k, both a record.
28-06
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2023
25-08
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema · 25 days late
2022
31-12
Financial
Weakest financial yearnet €296k ▼11%
Net result drops to €296k, the lowest in the series; recovery starts the following year.
30-08
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema · 30 days late
2021
30-08
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema · 30 days late
2020
28-08
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema · 28 days late
2019
28-08
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema · 28 days late
2018
31-08
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema · 31 days late
2017
31-08
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema · 31 days late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Belgian State Gazette reading coverage
We know of 3 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Credit advice
Company registry (CBE)
Activities
85120Specialist medical practice86220
Names & trade names
| Legal nameNL | DR RASOULI |
Similar companies
DOKTER VEERLE PEETERS
BE 0473.303.679 · Zonhoven
DOKTER J. VAN LIERDE
BE 0456.393.413 · Genk
DOCTEUR BLAISE PIERRE
BE 0837.613.608 · Verviers
DR. STEFAN ORIS
BE 0458.600.162 · Herentals
MICRUROL
BE 0818.627.342 · Herentals